The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Dec. 20, 12:08 AM

Slide #8. MEI Pharma, Inc. Secondary Offering

Company: MEI Pharma, Inc. (NASDAQ:MEIP)
Date announced: 12/10/2014
Shares Offered: 10,000,000
Date of Pricing: 12/12/2014
Price Per Share: $4.00
Secondary Offering Details: MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it plans to offer up to $45,000,000 of shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. - updated 12/12 - MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering of 10,000,000 shares of its common stock at an offering price of $4.00 per share, for total gross proceeds (before underwriting discount and commissions and estimated expenses) of approximately $40 million. The Company has granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of its common stock. The offering is expected to close on December 17, 2014, subject to customary closing conditions.

MEI Pharma is a development-stage oncology company focused on the clinical development of small molecules for the treatment of cancer. Co.'s lead drug candidate is Pracinostat. Pracinostat is an orally available histone deacetylase inhibitor that is being developed for hematologic diseases such as myelodysplastic syndrome and acute myeloid leukemia. Co.'s clinical development pipeline also includes two isoflavone-based drug candidates, ME-344 and ME-143. ME-344 and ME-143 are derived from an isoflavone technology platform that has generated a number of compounds with anti-tumor activity in laboratory studies.
Open the MEIP Page at The Online Investor »

Company Name:  MEI Pharma Inc
Website:  www.meipharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding MEIP:  1
Total Market Value Held by ETFs:  $189595
Total Market Capitalization:  $90.00M
% of Market Cap. Held by ETFs:  0.21%
 

Open the MEIP Page at The Online Investor (in a new window) »

December 20, 2014    12:08 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
93rd percentile
(ranked higher than approx. 93% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.